nvus-8k_20180613.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

__________________________________________________________________________________________

FORM 8-K

 

__________________________________________________________________________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

June 13, 2018
Date of Report
(Date of earliest event reported)

 

 

__________________________________________________________________________________________

 

Novus Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

__________________________________________________________________________________________

 

 

 

 

 

 

Delaware

(State or other jurisdiction

 of incorporation)

 

001-36620

(Commission

File Number)

 

20-1000967

(IRS Employer

Identification No.)

 

 

19900 MacArthur Blvd., Suite 550

Irvine, California 92612

(Address of principal executive offices, including Zip Code)

 

(949) 238-8090

(Registrant’s telephone number, including area code)

 

__________________________________________________________________________________________

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 

Item 5.07

Submission of Matters to a Vote of Security Holders.  

 

Novus Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on June 13, 2018 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted in the following manner with respect to the following proposals:

 

1.

The election of two Class I directors, each to serve for a three-year term expiring at the 2021 annual meeting of stockholders and until his/her successor has been duly elected and qualified.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nominees

  

      For     

 

  

  Withheld  

 

  

 Broker Non-Votes 

 

Erez Chimovits

  

 

2,563,826

 

 

 

147,799

 

 

 

2,950,332

  

Cheryl L. Cohen

  

 

2,568,656

 

 

 

142,969

 

 

 

2,950,332

  

 

2.

The ratification of the appointment of  Ernst & Young LLP  as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

 

 

 

 

 

For:

  

 

 

5,648,269  

Against:

  

 

 

3,624  

Abstain:

  

 

 

10,064  

 

 


2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

Novus Therapeutics, Inc.

 

 

 

 

 

 

 

Date: June 14, 2018

By:/s/ Gregory J. Flesher       

 

 

Name: Gregory J. Flesher

 

 

Title: Chief Executive Officer

 

 

 

 

 

3